International WELL Building Institute Opens Enrollment for WELL Health-Safety Rating In Response to COVID-19 With Significant Early Adoption
The International WELL Building Institute (IWBI) announced that enrollment has opened today for the WELL Health-Safety Rating for Facility Operations and Management, with more than 100 organizations and real estate portfolios across the globe already enrolled. Organizations across a wide range of industries and geographic locations have responded swiftly to implement the program’s science-backed guidance as they seek to instill confidence and trust among their staff, stakeholders and the broader community.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200708005768/en/
The WELL Health-Safety Rating is an evidence-based, third-party verified rating for all new and existing building and space types focused on operational policies, maintenance protocols, emergency plans and stakeholder engagement strategies to help organizations prepare their spaces for re-entry in a post COVID-19 environment.
Adapted from features in the WELL Building Standard (WELL) that focus on facilities, maintenance and operations, the WELL Health-Safety Rating is designed to guide and empower the actions of large and small businesses alike in taking the necessary steps to prioritize the health and safety of their staff, visitors and stakeholders. It also serves as an annual process that supports efforts to promote the long-term health and safety of people.
“We’re all eager to get back to our workplaces, back to school, back to traveling, dining, and cheering on our favorite teams and performers,” said IWBI Chairman and CEO Rick Fedrizzi. “As organizations across the globe respond to the COVID-19 crisis through changes in policies and protocols, the WELL Health-Safety Rating delivers the evidence-based health strategies required to help them safely reopen with the confidence and integrity provided by third-party verification.”
Created by IWBI, the WELL Health-Safety Rating is informed by guidance developed by the World Health Organization (WHO), U.S. Centers for Disease Control and Prevention (CDC), global disease control and prevention centers and emergency management agencies, recognized standard-making bodies, such as ASTM International and ASHRAE, and leading academic and research institutions. IWBI has leveraged insights from its Task Force on COVID-19, established at the outset of the pandemic to help business and building leaders integrate actionable insights and proven strategies in the fight against COVID-19 and other respiratory infections.
“This moment has highlighted the critical role that buildings, and those that own and operate them, can play in supporting people’s health, safety and well-being,” said IWBI President Rachel Gutter. “This new rating aims to meet the urgent need to deliver high health and safety standards in all of the spaces we occupy. While longer term design strategies are important in reducing the risks of infectious disease spread, this rating focuses on strategies that can be implemented immediately to address acute threats, using our buildings and spaces as a first line of defense in the fight against COVID-19.”
Demonstrating thought leadership and commitment to the health and safety of their stakeholder communities, the following leading organizations are among the first that have enrolled to achieve the WELL Health-Safety Rating:
|
ACCIONA SA |
|
Adventist Health |
|
Aedifica |
|
Alpin Limited (Masdar City) |
|
American Savings Bank |
|
Bartra Capital Property |
|
CAMCO Management Co. |
|
Carrier |
|
Catalyst Partners |
|
CBD Z03 |
|
CBRE Barcelona |
|
CBRE Madrid |
|
China Overseas Office Capital |
|
Cleveland Clinic Courts / Cleveland Cavaliers |
|
Climate Change Arena |
|
Community Investment Strategies, Inc |
|
CR Land |
|
Deerns |
|
Delos China |
|
Delos Living LLC |
|
Delta Electronics, Inc. |
|
Denholtz Properties |
|
Department of Earth System Science, Tsinghua University |
|
Empire State Realty Trust |
|
EMSI |
|
GFP Real Estate |
|
Ghelamco Poland Sp. z o.o. |
|
Glenstar |
|
GuocoLand China Ltd. |
|
HBMSU |
|
Heitman |
|
Herman Miller Group |
|
Hornets Sports & Entertainment - Spectrum Center |
|
HRO |
|
Infancix Co., Ltd |
|
International Commerce Centre |
|
International WELL Building Institute PBC |
|
Ivanhoé Cambridge |
|
Jiahui Health |
|
JLL |
|
Karisma Hotels and Resorts |
|
Kilroy Realty Corporation |
|
Kimball |
|
Laguna |
|
Lendlease Australia Office Portfolios: Australian Prime Property Fund Commercial, Lendlease International Towers Sydney Trust and Lendlease One International Towers Sydney Trust |
|
Lincoln Property Company |
|
M Moser Associates |
|
Mace |
|
Maple Leaf Sports & Entertainment (MLSE), which encompasses the Toronto Maple Leafs (NHL), Toronto Raptors (NBA), Toronto FC (MLS), & Toronto Argonauts (CFL) |
|
Menarco Development Corporation |
|
Milliken & Company |
|
ML7 |
|
Montage International |
|
Moody Center
|
|
New Belmont Arena |
|
New York Yankees |
|
Oak View Group |
|
Out of the Box Ventures |
|
Overbury Morgan Lovell |
|
OVG Arena Alliance & Stadium Alliance |
|
OVG Facilities |
|
Pacers Sports & Entertainment: Bankers Life Fieldhouse (Indianapolis, Ind.) |
|
Pacers Sports & Entertainment: St. Vincent Center/Indiana Pacers Training Facility (Indianapolis, Ind.) |
|
Parmenter Realty Partners |
|
Phipps Conservatory and Botanical Gardens |
|
RMZ Corp |
|
Rocket Mortgage FieldHouse / Cleveland Cavaliers & Cleveland Monsters |
|
Royal Albert Hall |
|
Rubrik India Pvt Ltd |
|
Savanna |
|
Serpentini Auto Group |
|
Shanghai Landleaf Architecture Technology Co. Ltd |
|
ShouGang Group |
|
Sino-Ocean |
|
Space Matrix Design Consultants Pvt. Ltd
|
|
TAIPEI 101 Tower |
|
Taiwan Architecture & Building Center |
|
Teknion |
|
The Florida Panthers and BB&T Center |
|
The Forestias |
|
The Related Group |
|
Thornton Tomasetti |
|
TITANIUM OFFICE SOLUTIONS MEXICO |
|
Uber Technologies, Inc. |
|
UltraStar Harrah’s Ak Chin Resort Maricopa, Az. |
|
United Center |
|
Webster Bank Arena |
|
Wells Fargo Center, Philadelphia, Pa. |
|
Wolfgang Puck Fine Dining Group |
|
Woonerf Inc. |
|
Yuexiu Commercial |
Upon achieving the designation, IWBI will issue the building or space a WELL Health-Safety seal.
The WELL Health-Safety Rating draws on principles established by IWBI’s WELL Building Standard, the premier standard for healthy real estate, which has surpassed 590 million square feet in registrations across 62 countries since inception. The WELL Building movement has been further amplified by over 12,000 WELL Accredited Professionals (APs) and registrants across the globe.
To learn more about the WELL Health-Safety Rating and to enroll, please visit www.wellcertified.com/health-safety.
About the International WELL Building Institute
The International WELL Building Institute (IWBI) is leading the global movement to transform our buildings, communities and organizations in ways that help people thrive. The WELL v2 pilot is the latest version of its popular WELL Building Standard (WELL), and the WELL Community Standard pilot is a district scale rating system that sets a new global benchmark for healthy communities. WELL is focused exclusively on the ways that buildings and communities, and everything in them, can improve our comfort, drive better choices, and generally enhance, not compromise, our health and wellness. IWBI mobilizes the wellness community through management of the WELL AP credential, the pursuit of applicable research, the development of educational resources, and advocacy for policies that promote health and wellness everywhere. IWBI is a participant of the United Nations Global Compact, the world’s largest corporate citizenship initiative, and helps companies advance the UN Sustainable Development Goals (SDGs) through the use of WELL. More information on WELL can be found here.
International WELL Building Institute, IWBI, the WELL Building Standard, WELL v2, WELL Certified, WELL AP, WELL, WELL Portfolio, The WELL Conference, the WELL Community Standard, WELL Health-Safety Rating and others, and their related logos are trademarks or certification marks of International WELL Building Institute pbc in the United States and other countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200708005768/en/
Contact information
Media:
Judith Webb
media@wellcertified.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
Vertex Presents New Data on CASGEVY ® , Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 14:01:00 EET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and TDT ages 12 years and older, will be presented at the American Society of Hematology (ASH) Annual Meeting. CASGEVY is currently approved for eligible people ages 12 years and older with SCD or TDT in the United States, Great Britain, the European Union, the Kingdom of Saudi Arabia, the Kingdom of Bahrain, Kuwait, Qatar, Canada, Switzerland and the United Arab Emirates. “These results — the first clinical data ever presented on any genetic therapy for children ages 5-11 years with SCD — again demonstrate the tr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
